LAB
Standard Biotools Inc
Standard Biotools Inc historical holders
total: 2
Disciplined Growth Investors Standard Biotools Inc transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2020 Q4
- Held for:
- 1 quarter
- Latest activity:
- 2021 Q1
Fred Martin has been an institutional investor in Standard Biotools Inc (LAB) since 2020 Q4. According to 2026 Q1 report, Fred Martin doesn't hold any shares. The fund/company first acquired LAB in 2020 Q4, initially purchasing 10,000 shares. Since the initial investment, Disciplined Growth Investors has made 1 more transaction in this position.
When did Fred Martin exit their LAB position?
Fred Martin no longer holds Standard Biotools Inc (LAB). They sold off their entire position in 2021 Q1, closing out an investment that began in 2020 Q4.
When did Fred Martin first invest in LAB?
Fred Martin first invested in Standard Biotools Inc (LAB) in 2020 Q4 at the reported quarter-end price of $6.00 per share, acquiring 10,000 shares in their initial purchase.
What is Fred Martin's average cost basis for LAB?
Based on historical transaction data, Fred Martin's estimated cost basis for Standard Biotools Inc (LAB) is approximately $6.00 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $6.00
- Weighted AVG sell price:
- $6.00
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.